posted on 2022-02-07, 13:44authored byTaylor & FrancisTaylor & Francis, Beth L. Nordstrom, Melissa Hamilton, Jenna M. Collins, Dennis Earle, Ying Zhang, Shivani Srivastava, Leonel Hernandez-Aya
Supplemental
Table 1. Treatment Patterns after Index Line for the Anti-programmed Cell
Death-1-treated Patients with Advanced Melanoma Treated with a BRAF
Therapy in the Index Line or Prior to Index
Supplemental
Table 2. Baseline Demographic Characteristics for Patients with Advanced
Melanoma, Died on Index, by BRAF Status
Supplemental
Table 3. Baseline Clinical Characteristics for Patients with Advanced
Melanoma, Died on Index, by BRAF Status
Supplemental
Table 4. Treatment Characteristics in Baseline, Died on Index, by BRAF
Status
Supplemental
Table 5. BRAFmt and BRAFwt Overall Survival from the Index
Date, Stratified by Receipt of Index Anti-PD-1 After Progression